GPO announces NDV-HXP-S COVID-19 vaccine candidate (HXP-GPOVac) has entered phase 3 clinical evaluation.
Mr. Anutin Charnweerakul, Deputy Prime Minister of Thailand and the Minister of Public Health announces that GPO’s NDV-HXP-S COVID-19 vaccine candidate (HXP-GPOVac) has entered phase 3 clinical evaluation as a booster dose at Nakhon Phanom Hospital in Nakhon Phanom Province on 20th December 2022. The study is recruiting 4,000 volunteers 18 years of age and older, who were immunized with 2 doses of COVID-19 vaccine as a primary vaccination.
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route
Here we evaluated a vaccine candidate based on a live recombinant Newcastle disease virus (NDV) that expresses a stable version of the spike protein in infected cells as well as on the surface of the viral particle (AVX/COVID-12-HEXAPRO, also known as NDV-HXP-S). We evaluated this vaccine candidate in prime-boost regimens via intramuscular, intranasal, or intranasal followed by intramuscular routes in an open-label non-randomized non-placebo controlled phase I clinical trial in Mexico in 91 volunteers.
The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNAvaccines
Secondary analysis of GPO / Thai Phase 1 trial results. NDV-HXP-S was compared to Pfizer and showed RBD (Receptor Binding Domain) focused response, and higher ratio of neutralizing to non-neutralizing antibodies compared to Pfizer.
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
Phase 1 trial results of NDV-HXP-S (NDV with spike protein) in Thailand via the Government Pharmaceutical Organization (GPO). Results show that NDV-HXP-S has an acceptable safety profile and potent immunogenicity.
New York Times: Researchers Are Hatching a Low-Cost Coronavirus Vaccine
A new formulation entering clinical trials in Brazil, Mexico, Thailand and Vietnam could change how the world fights the pandemic.